From AI Pilots to Patient Impact: Scaling Healthcare Innovation
By Noah Gula
Healthcare has no shortage of AI pilots. Across health systems today, organizations are experimenting with everything from patient engagement tools and predictive analytics to ambient documentation and clinical decision support. The challenge is turning an experiment into something that reliably improves care.
That gap is where many healthcare AI investments lose momentum. In my work helping health systems, payers, and digital health organizations move AI from concept to operational reality, I’ve seen a consistent pattern: the model itself is rarely the hardest part. The real work is designing the environment around it, the data foundation, governance, workflow, and economics required for adoption to hold. The gap is measurable: a 2026 Qventus survey of more than 60 CIOs, chief AI officers, and senior IT leaders at large U.S. health systems found that only 4% reported scaled AI implementation with measurable outcomes. Healthcare organizations are moving beyond experimentation, but few have translated that into measurable enterprise-scale impact.
These four disciplines consistently matter more than organizations expect.
Interoperability is the foundation
An AI solution’s production success depends heavily on the data ecosystem supporting it. Consider a prior-authorization workflow: a model may test well, but production depends on whether eligibility data, clinical documentation, and payer requirements move reliably between systems. Incomplete integrations can make capable technology look ineffective when the real constraint is infrastructure that cannot scale; the model didn’t fail, the data path failed to support it. In one roll-out I supported, a well-tested model stalled for months because eligibility data from three payer portals never reliably reached the tool; the fix was a data-mapping exercise, not a model retrain.
Qventus’ 2026 CIO research found that 74% of health-system technology leaders identified electronic health record (EHR) vendor dependency as a top barrier to scaling AI, reinforcing a point I raise with every client: the model may be ready, but the surrounding technology ecosystem often isn’t.
In practice, I map the data journey before I evaluate the AI journey. If you can’t describe what the system reads, where its output goes, and what happens when data is missing, you’re not ready to scale.
Governance cannot be added after success
A familiar pattern: a pilot proves value, leadership gets excited, and only then are legal, security, and clinical stakeholders asked to solve problems that should have been considered during design. A deterioration-risk model raises real questions before go-live: who responds to the alert, how a clinician overrides it, and who monitors performance over time. Answering those during design, not after, separates a pilot that scales from one that stalls.
I treat governance as part of the architecture, not an approval step added after a pilot succeeds.
Workflow adoption determines whether AI reaches patients
An ambient documentation tool may perform well in a demo and still struggle at scale once it meets different specialties, templates, and levels of clinician trust. Now the question is “Does it reliably fit how clinicians actually work?” I’ve watched adoption stall this way: a tool that tested well in one department needed months of template tuning before other specialties trusted it, and until then, clinicians simply worked around it, leaving the patient visit just as inefficient.
The unit of scale is the actual workflow, not the model. Adoption needs as much design rigor as accuracy does.
A successful pilot rarely means enterprise readiness
A pilot with a small group of clinicians and a few integration points can look successful and still not reveal what thousands of users across multiple facilities will cost to support and maintain. Before scaling, leadership should know the cost per user or encounter and weigh it against measurable value, not assume a good pilot is automatically affordable enterprise-wide.
A pilot proves feasibility. Scale proves economics. Know the operating cost before assuming a good pilot is ready for rollout.
Measuring what ties it together
Accuracy is only one measure of success. An AI initiative should also be judged on whether it integrates reliably, earns clinician adoption, justifies its cost, and, most of all, improves something patients actually feel: fewer repeated questions, shorter waits, faster answers, and more time with a clinician who isn’t fighting the technology.
None of these four disciplines is really about building a better algorithm. Interoperability determines whether AI can access the data it needs, governance whether it can operate responsibly, workflow and trust whether people will use it, and economics whether the organization can sustain it. Organizations most likely to scale AI successfully treat these as one connected challenge from the first pilot conversation, not issues to solve after the technology is built.
Author Bio: Noah Gula, AVP at OSP